Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
December 14, 2023 19:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics...
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
September 22, 2023 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics...
Neurogene and Neoleukin Announce Definitive Merger Agreement
July 18, 2023 06:30 ET
|
Neoleukin Therapeutics, Inc.
Proposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene’s differentiated portfolio of genetic medicines for complex neurological diseases Combined company is expected...
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
March 08, 2023 17:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo...
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
December 12, 2022 13:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo...
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
November 14, 2022 16:03 ET
|
Neoleukin Therapeutics, Inc.
-- Development of NL-201 to be discontinued for strategic reasons ---- Company to focus on next-generation de novo proteins and core technology ---- Company restructuring to extend cash runway into...
Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
November 03, 2022 09:05 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo...
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
August 09, 2022 16:02 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo...
Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
July 27, 2022 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022...